Clinical Trials
14 trialsNCT07145411 2025-08-28
HOPE
Ossium Health, Inc.
Recruiting
NCT06539169 2024-11-14
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
xCures
Recruiting
NCT05635266 2024-05-07
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Sanguine Biosciences
Unknown
NCT01931644 2024-04-18
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Sanguine Biosciences
Completed
NCT02065869 2023-09-29
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
Bellicum Pharmaceuticals
Phase 1/2 Terminated
NCT03733249 2023-09-26
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
Bellicum Pharmaceuticals
Phase 1/2 Terminated
NCT03036813 2023-07-27
GBT_HOPE
Pfizer
Phase 3 Completed
NCT01179217 2020-08-19
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
Emmaus Medical, Inc.
Phase 3 Completed
NCT02516579 2020-03-19
ESCORT-HU
Theravia
Completed
NCT01895361 2020-01-31
SUSTAIN
Reprixys Pharmaceutical Corporation
Phase 2 Completed
NCT00236041 2014-05-09
Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT00236093 2014-05-09
Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT01206907 2012-08-17
Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects
Endo Pharmaceuticals
Phase 3 Withdrawn
NCT00596999 2012-04-10
HPDSC
Celgene
Unknown